Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Glaukos Corporation · NCT06057051
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 35+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 245
- US sites recruiting
- 1
- Study start
- September 1, 2023
- Record last updated
- September 28, 2023
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Being studied: iStent Infinite
Conditions: Glaucoma
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Diagnosis of primary open-angle glaucoma
- Phakic or pseudophakic
- Age 35 years or older
Exclusion Criteria
- Traumatic, uveitic, neovascular, angle-closure glaucoma or
- glaucoma associated with vascular disorders
- Active corneal inflammation or edema
- Retinal disorders not associated with glaucoma
Recruiting US locations
Glaukos Investigator Site
Cincinnati, OH 45242
Site contact: Dari Parizadeh
Study contacts (from the official record)
- Dari Parizadeh · 949-481-0575 · dparizadeh@glaukos.com
- Kerry Stephens · 949-481-8057 · kstephens@glaukos.com